trending Market Intelligence /marketintelligence/en/news-insights/trending/6wa0aqfamr1mpanzlbgwuq2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Flex Pharma pulls plug on phase 2 ALS trial, plans 60% workforce cut

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Flex Pharma pulls plug on phase 2 ALS trial, plans 60% workforce cut

Flex Pharma Inc. is ending its phase 2 study to treat two degenerative disorders after concerns that patients could not tolerate three daily doses of its experimental pill.

The Boston-based biotech also said it will slash its workforce by 60% in the coming weeks, with most of its restructuring measures announced by June 30.

A subset of patients in the phase 2 trial for FLX-787 — which looked at the therapy for both amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, and another degenerative nerve disorder, Charcot-Marie-Tooth — showed oral intolerability at the current 30-milligram dose and formulation.

The data indicate that more formulation and dose-range studies are needed, President and CEO Bill McVicar said in Flex Pharma's statement, adding that such studies are "challenging for the company based on our current resources."

Flex Pharma had previously reported positive data for the drug in multiple sclerosis and ALS that "demonstrate the clear potential of FLX-787 as a symptomatic therapy to reduce painful cramps and spasms in these patient populations," McVicar said.

The company is now reviewing its options, with Wedbush PacGrow brought on as a strategic financial adviser, with the possibility of both a company sale or merger on the table.

The remaining Flex Pharma staff will focus on FLX-787 in dysphagia, or difficulty swallowing, and operate its consumer business. The layoffs and restructuring will cost between $800,000 and $1 million in one-time fees but realize cost-savings starting in the third quarter of 2018, Flex estimated.